Fatty Acid Oxidation is Impaired in An Orthologous Mouse Model of Autosomal Dominant Polycystic Kidney Disease

被引:128
|
作者
Menezes, Luis F. [1 ]
Lin, Cheng-Chao [1 ]
Zhou, Fang [1 ]
Germino, Gregory G. [1 ]
机构
[1] NIDDK, NIH, Bethesda, MD 20892 USA
来源
EBIOMEDICINE | 2016年 / 5卷
关键词
Polycystic kidney disease; Autosomal Dominant Polycystic Kidney Disease; Pkd1; ADPKD; Mouse model; Systems biology; Metabolism; Fatty acid oxidation; Fatty acid oxidation defect; Lipid metabolism; Diet; PLANAR CELL POLARITY; SEX-DIFFERENCES; ILLUMINA MICROARRAY; ENERGY HOMEOSTASIS; INSULIN-RESISTANCE; NETWORK ANALYSIS; CYST FORMATION; IN-VIVO; PKD1; EXPRESSION;
D O I
10.1016/j.ebiom.2016.01.027
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: The major gene mutated in autosomal dominant polycystic kidney disease was first identified over 20 years ago, yet its function remains poorly understood. We have used a systems-based approach to examine the effects of acquired loss of Pkd1 in adult mouse kidney as it transitions from normal to cystic state. Methods: We performed transcriptional profiling of a large set of male and female kidneys, along with metabolomics and lipidomics analyses of a subset of male kidneys. We also assessed the effects of a modest diet change on cyst progression in young cystic mice. Fatty acid oxidation and glycolytic rates were measured in five control and mutant pairs of epithelial cells. Results: We find that females have a significantly less severe kidney phenotype and correlate this protection with differences in lipid metabolism. We show that sex is a major determinant of the transcriptional profile of mouse kidneys and that some of this difference is due to genes involved in lipid metabolism. Pkd1 mutant mice have transcriptional profiles consistent with changes in lipid metabolism and distinct metabolite and complex lipid profiles in kidneys. We also show that cells lacking Pkd1 have an intrinsic fatty acid oxidation defect and that manipulation of lipid content of mouse chow modifies cystic disease. Interpretation: Our results suggest PKD could be a disease of altered cellular metabolism. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
引用
收藏
页码:183 / 192
页数:10
相关论文
共 50 条
  • [1] Sirolimus attenuates disease progression in an orthologous mouse model of human autosomal dominant polycystic kidney disease
    Zafar, Iram
    Ravichandran, Kameswaran
    Belibi, Franck A.
    Doctor, R. Brian
    Edelstein, Charles L.
    KIDNEY INTERNATIONAL, 2010, 78 (08) : 754 - 761
  • [2] The role of PPARα in autosomal dominant polycystic kidney disease
    Lakhia, Ronak
    CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION, 2020, 29 (04) : 432 - 438
  • [3] Perspectives of Gene Therapies in Autosomal Dominant Polycystic Kidney Disease
    Xu, Yuchen
    Li, Ao
    Wu, Guanqing
    Liang, Chaozhao
    CURRENT GENE THERAPY, 2017, 17 (01) : 43 - 49
  • [4] Autosomal Dominant Polycystic Kidney Disease
    Perumareddi, Parvathi
    Trelka, Darin P.
    PRIMARY CARE, 2020, 47 (04): : 673 - 689
  • [5] Metformin improves relevant disease parameters in an autosomal dominant polycystic kidney disease mouse model
    Pastor-Soler, Nuria M.
    Li, Hui
    Pham, Jessica
    Rivera, Daniel
    Ho, Pei-Yin
    Mancino, Valeria
    Saitta, Biagio
    Hallows, Kenneth R.
    AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY, 2022, 322 (01) : F27 - F41
  • [6] α-lipoic acid in patients with autosomal dominant polycystic kidney disease
    Lai, Silvia
    Petramala, Luigi
    Muscaritoli, Maurizio
    Cianci, Rosario
    Mazzaferro, Sandro
    Mitterhofer, Anna Paola
    Pasquali, Marzia
    D'Ambrosio, Viola
    Carta, Maria
    Ansuini, Matteo
    Ramaccini, Cesarina
    Galani, Alessandro
    Amabile, Maria Ida
    Molfino, Alessio
    Letizia, Claudio
    NUTRITION, 2020, 71
  • [7] Recognizing and treating autosomal dominant polycystic kidney disease
    Uko, Chigozie G.
    NURSE PRACTITIONER, 2020, 45 (11) : 41 - 47
  • [8] Molecular diagnosis of autosomal dominant polycystic kidney disease
    Balcells, R. Torra
    Criach, E. Ars
    NEFROLOGIA, 2011, 31 (01): : 35 - 43
  • [9] Targeted Therapies for Autosomal Dominant Polycystic Kidney Disease
    Stayner, Cherie
    Brooke, Darby G.
    Bates, Michael
    Eccles, Michael R.
    CURRENT MEDICINAL CHEMISTRY, 2019, 26 (17) : 3081 - 3102
  • [10] Nonpharmacological Management of Autosomal Dominant Polycystic Kidney Disease
    Steele, Cortney N.
    Nowak, Kristen L.
    ADVANCES IN KIDNEY DISEASE AND HEALTH, 2023, 30 (03): : 220 - 227